Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Related Posts
Atos Launches $252 Million Capital Increase
The troubled IT firm said it would issue new shares in its latest move to reduce debt.
Companies Like to Pit Internal Teams Against Each Other. Bad Idea.
Research suggests that when employees compete, they become less innovative, because they don’t want to share ideas with their rivals.
Shoppers Are Picky Heading Into Black Friday. Retailers Could Win or Lose Big.
Companies say shoppers are still buying, but they want a deal.